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Vitamin E (a-tocopherol) is an essential dietary nutri-
ent for humans and animals. The mechanisms involved
in cellular regulation as well as in the preferential cel-
lular and tissue accumulation of a-tocopherol are not
yet well established. We previously reported (Stocker,
A., Zimmer, S., Spycher, S. E., and Azzi, A. (1999) IUBMB
Life 48, 49–55) the identification of a novel 46-kDa toco-
pherol-associated protein (TAP) in the cytosol of bovine
liver. Here, we describe the identification, the molecular
cloning into Escherichia coli, and the in vitro expression
of the human homologue of bovine TAP, hTAP. This
protein appears to belong to a family of hydrophobic
ligand binding proteins, which have the CRAL (cis-reti-
nal binding motif) sequence in common. By using a bi-
otinylated a-tocopherol derivative and the IASys reso-
nant mirror biosensor, the purified recombinant protein
was shown to bind tocopherol at a specific binding site
with Kd 4.6 3 10
27 M. Northern analyses showed that
hTAP mRNA has a size of approximately 2800 base pairs
and is ubiquitously expressed. The highest amounts of
hTAP message are found in liver, brain, and prostate. In
conclusion, hTAP has sequence homology to proteins
containing the CRAL TRIO structural motif. TAP binds
to a-tocopherol and biotinylated tocopherol, suggesting
the existence of a hydrophobic pocket, possibly analo-
gous to that of SEC14.
Vitamin E is a physiological component of cellular mem-
branes and lipoproteins. Since its discovery in 1922 by Evans
and Bishop (1), researchers have confirmed the significance of
a-tocopherol as the principal vitamin E homologue in human
plasma (2). Roles in the maintenance of tissue integrity (3) in
the prevention of atherosclerosis (4) and prostate cancer (5) as
well as in the regulation of the immune response (6) have been
proposed. Most of these effects have been attributed to two
primary functions of a-tocopherol. One function of a-tocopherol
is as a scavenger of reactive oxygen (7) and nitrogen species (8)
able to break radical chain propagation reactions (9). The other
function of a-tocopherol, more recently elucidated, is an addi-
tional role consisting of a structure-specific modulation of cel-
lular functions such as adhesion (10), proliferation (11), and
apoptosis (12). Decreased levels of a-tocopherol can thus evoke
unspecific damage to lipid, protein, and DNA caused by the
unscavenged reactive oxygen and nitrogen species; they can, at
the same time, induce defined cellular responses, which cannot
be neutralized by a-tocopherol-related phenolic antioxidants
(13, 14). The latter events can be related to a-tocopherol-in-
duced protein kinase C inhibition (15), to the activation of the
nuclear transcription factor kB (16), and to the modulation of
the expression of specific genes, e.g. the gene of collagenase 1
(17), the gene of a-tropomyosin (18), and the gene for one of the
scavenger receptors (19). These cellular events require specific
recognition molecules that are able to bind tocopherol and feed
this information further into the cell signaling pathways. Fur-
thermore, due to its strong hydrophobicity and its primary
location in the plasma membrane, a-tocopherol requires a car-
rier mechanism, which can regulate its cytosolic transport to
other cellular sites. The mechanism by which a-tocopherol is
redistributed within the cell and reaches mitochondria and the
nucleus has not been studied.
Nutrition-related vitamin E deficiency in humans is a rare
situation, although several lines of evidence support a relation-
ship between low levels of a-tocopherol and human diseases,
e.g. increased risk of atherosclerosis and prostate cancer. Re-
cently, a group of patients having remarkably low levels of
plasma a-tocopherol were studied in Tunisia (20, 21). In these
patients, a genetic defect of an a-tocopherol-specific liver pro-
tein (a-TTP)1 caused the disruption of tocopherol transfer from
chylomicrons into plasma lipoproteins and a clinical syndrome,
AVED (ataxia with isolated vitamin E deficiency). When these
patients were given a high dose of a-tocopherol, the progression
of the disease was reduced (22).
If a binding protein is needed for a-tocopherol transfer from
chylomicrons via liver into plasma, it is important to ask if
other proteins might be responsible for the distribution of a-to-
copherol to intracellular compartments. Indeed a number of
studies have been carried out in an attempt to isolate and
characterize such proteins (23, 24).
Using radioactively labeled a-tocopherol as a tracer we have
recently identified and briefly described a new a-tocopherol
binding protein of molecular mass 46 kDa in the cytosol of
bovine liver, which has been called a-tocopherol-associated pro-
tein (TAP) (25). In this paper, we present the identification,
* This study was made possible by the support of the Swiss National
Science Foundation, by a grant of the Henkel Corporation, and by the
Stiftung fu¨r die Erna¨hrungsforschung in der Schweiz. The costs of
publication of this article were defrayed in part by the payment of page
charges. This article must therefore be hereby marked “advertisement”
in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
§ These authors contributed equally to this work.
¶ To whom correspondence should be addressed: Tel.: 41-31-631-
4129; Fax: 41-31-631-3737; E-mail: achim.stocker@mci.unibe.ch.
1 The abbreviations used are: a-TTP, a-tocopherol-transfer protein;
bTAP/hTAP, bovine/human a-tocopherol-associated protein; CRAL, cis-
retinal binding motif; SEC14, SEC14 cytosolic factor; His-hTAP, histi-
dine-tagged human a-tocopherol-associated protein; IASys, interaction
analysis system; HPLC, high performance liquid chromatography; RT-
PCR, reverse transcription-polymerase chain reaction; PAGE, poly-
acrylamide gel electrophoresis; BSA, bovine serum albumin; kb,
kilobase(s).
THE JOURNAL OF BIOLOGICAL CHEMISTRY Vol. 275, No. 33, Issue of August 18, pp. 25672–25680, 2000
© 2000 by The American Society for Biochemistry and Molecular Biology, Inc. Printed in U.S.A.
This paper is available on line at http://www.jbc.org25672
 at U
niversitaetsbibliothek Bern on M
arch 11, 2020
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
s
o
u
r
c
e
:
 
ht
tp
s:
//
do
i.
or
g/
10
.7
89
2/
bo
ri
s.
14
17
61
 
| 
do
wn
lo
ad
ed
: 
16
.3
.2
02
0
molecular cloning, and the in vitro expression of the human
homologue of TAP. The kinetic data of the interaction between
recombinant TAP and a biotinylated tocopherol derivative are
presented. In addition, the results of a structural analysis of its
lipid binding domain and studies on the distribution of TAP in
human tissues are reported.
EXPERIMENTAL PROCEDURES
Materials—Tritiated D-a-tocopherol (24.76 Ci/mmol) was synthe-
sized by Amersham Pharmacia Biotech and further purified on a Nova-
Pak C18 HPLC column from Millipore Corp. (Bedford, MA) using meth-
anol/water (96/4, v/v) as the mobile phase and stored at 220 °C under
nitrogen. The purity of D-a-[3H]tocopherol was checked during the
course of the studies by HPLC and/or by thin layer chromatography.
The radioactivity was measured with a Packard liquid scintillation
analyzer (Tri-Carb 2100 TR) using Irga-Safe Plus from Packard (Meri-
den, CT). All other analytical-grade chemicals were obtained from
Sigma or Merck (Darmstadt, Germany).
Preparation of Bovine Liver Cytosol—Bovine liver was obtained from
freshly slaughtered calves. The liver was perfused with a physiological
NaCl solution, divided into portions, and frozen at 280 °C for future
use. Thawed liver was homogenized using a Polytron homogenizer
(Kinematica GmbH, Switzerland) with 2 volumes of homogenization
buffer consisting of 0.01 M sodium phosphate, pH 7.4, 0.25 M sucrose,
and 1 mM phenylmethylsulfonyl fluoride. All further purification steps
were carried out at 4 °C. The homogenate was centrifuged at 5000 3 g
for 15 min to remove crude particles and whole cells. After ultracentrif-
ugation of the supernatant at 140,000 3 g for 90 min the obtained
cytosol was stored in portions at 280 °C.
Gel Filtration—For gel filtration 80 ml of cytosol was mixed with 5
mCi of a-[3H]tocopherol, incubated while stirring for 2 h at 4 °C, and
fractionated on a 5- x 80-cm Sephacryl S-200 gel column (Pharmacia
Fine Chemicals, Uppsala, Sweden) using a 0.01 M sodium phosphate
buffer, pH 7.4 (buffer A). Fractions of 10 ml were collected, and the
radioactivity of each fraction was measured.
Affinity Chromatography—The pooled tocopherol binding fractions
from the gel filtration were incubated while stirring overnight at 4 °C
with 2.5 mCi of a-[3H]tocopherol. A 0.6- x 40-cm Affi-Gel Blue column
(Bio-Rad) was equilibrated with buffer A. The incubation mixture was
applied to the column, which was subsequently washed with 100 ml of
the same buffer. Proteins were eluted with a linear NaCl gradient,
consisting of 400 ml of buffer A and 400 ml of buffer A with 1.1 M NaCl
and 2 mM EDTA. Fractions of 10 ml were collected and monitored for
radioactivity.
Ion Exchange Chromatography—A Mono S HR 5/20 column (Amer-
sham Pharmacia Biotech) was equilibrated with 0.02 M sodium phos-
phate, pH 6.5 (buffer B) at 4 °C. The pooled fractions from the first
radioactive peak of the Affi-Gel Blue chromatography were concen-
trated and equilibrated with buffer B by ultrafiltration using Cen-
triplus 10 concentrators (Amicon Inc., Beverly, MA) to 4 ml. After
incubation for 1 h with 2.5 mCi of a-[3H]tocopherol at 4 °C, the sample
was applied to the column and the column was washed with 5 ml of the
same buffer. For elution a linear NaCl gradient consisting of 12.5 ml of
buffer B and 12.5 ml of buffer B with 1 M NaCl was run. Fractions of 1
ml were collected and monitored for radioactivity.
Photographic Cross-linking—Protein fractions containing radioac-
tive tocopherol were irradiated for 30 s in a self-made device consisting
of a 1-ml quartz cuvette, cooled to 4 °C, and placed at a 5-cm distance to
a 150-watt xenon lamp.
Gel Electrophoresis, Isoelectric Focusing, and Fluorography—The pu-
rity of the a-[3H]tocopherol-containing fractions was tested by SDS-
PAGE (26), and gels were stained with Coomassie Brilliant Blue R-250.
Native isoelectric focusing was performed on Servalyt Precotes 3–10
precast gels as described by the manufacturer (Serva, Heidelberg, Ger-
many). Briefly, proteins were focused at 1500 V for 3500 volt-hours at
4 °C using 1 M NaOH as catholyte buffer and 1 M H3PO4 as anolyte
buffer. The gels were fixed with 20% trichloroacetic acid and stained in
Serva Violet 17. Fluorography was carried out by incubating the gels for
30 min with 1 M sodium salicylate and subsequent drying and exposure
to Biomax mass spectrometry film (Eastman Kodak Co.).
Reversed-phase HPLC—For the final purification of TAP and also for
the separation of peptide digests, obtained by cyanogen bromide cleav-
age, reversed-phase HPLC was performed. The samples were adjusted
with distilled water to 50 ml and loaded onto a Nova-Pak C4 reversed-
phase column (Millipore Corp.). A linear acetonitrile gradient (0–100%,
0.1% trifluoroacetic acid) at a flow of 0.5 ml/min was used for the
separations. Elution of proteins or peptides was detected at 225 nm in
the UV channel and at the same time at 280-nm excitation and 320-nm
emission in the fluorescent channel. Fractions of 0.5 ml were taken, and
the samples were lyophilized in a Speedvac concentrator (Savant, Mu-
nich, Germany).
Cyanogen Bromide Cleavage—Mono S fractions containing the high-
est radioactivity were desalted and concentrated to 30 ml with Microcon
10 microconcentrators (Amicon Inc.) and mixed with 470 ml of 8 M urea,
0.4 M ammonium bicarbonate, pH 8.0. Reduction was achieved by
15-min incubation at 55 °C in the presence of 25 ml of 100 mM dithio-
threitol. For carboxyamidation, 20 ml of 0.5 M iodoacetamide was added
and the sample was kept for 15 min at room temperature in the dark.
The sample was dissolved to 1 ml with distilled water and again
concentrated to 30 ml. After adding 70 ml of 100% formic acid, the
sample was cleaved with 3 ml of 5 M CNBr under nitrogen for 24 h in the
dark. To remove formic acid the sample was exposed to a nitrogen flow
for 30 min.
Amino Acid Sequencing of Peptide Fragments and Homology
Search—The isolated peptides were sequenced by automated Edman
degradation using a pulsed liquid-phase sequencer 477A on line with a
phenylthiohydantoin analyzer (PE Applied Biosystems, Foster City,
CA). The obtained amino acid sequences were analyzed with the EMBL/
GenBank™ data bases. The BLAST algorithm was used to search for
proteins homologous to bovine TAP.
Cloning of Human and Bovine TAP—The coding area of the cDNA for
human TAP was amplified by RT-PCR using total RNA from human
small colon as template. Oligonucleotide primers were synthesized
based on the genomic TAP sequence with a sense oligonucleotide primer
(59-ATGAGCGGCAGAGTCGGCGA-39) and an antisense oligonucleo-
tide primer (59-TTATTTCGGGGTGCCTGCCCCCA-39) (Microsynth,
Balgach, Switzerland). PCR was carried out by using the GeneAmp
RNA PCR Kit (Perkin-Elmer) in a GeneAmp PCR System 9700 (PE
Applied Biosystems). RT-PCR conditions were: reverse transcription for
15 min at 42 °C, denaturation for 5 min at 99 °C, and cooling for 5 min
at 5 °C. Half of the resulting cDNA was subjected to 40 cycles of PCR
under the following conditions: 30 s at 94 °C, 30 s at 68 °C, and 90 s at
72 °C. 1 ng of the obtained cDNA was used for reamplification in 30
cycles under the same conditions. The resulting PCR product was
purified with the JETsorb gel extraction kit (Genomed, Bad Oeyn-
hausen, Germany) and subcloned into the pGEM-T vector (Promega,
Madison, WI). The construct was transformed into JM101 competent
cells using electroporation with 1800 V, 25 microfarads, and 200 ohms
in a Gene Pulser II electroporation system (Bio-Rad). Clones were
sequenced using M13 forward and reverse oligonucleotide primers (Mi-
crosynth), and sequence analysis was done using the Wisconsin Se-
quence Analysis Package (version 9.1).
Bovine TAP was cloned using primers designed from the human
sequence. Total RNA from bovine liver was purified using the RNeasy
Mini Kit (Qiagen, Basel, Switzerland). RT-PCR and PCR were per-
formed as described above with a sense oligonucleotide primer (59-
ATGAGCGGCAGAGTCGGCGA-39) and an antisense oligonucleotide
primer (59-GTCTGGAAGCAGGACCTCCAC-39) (Microsynth). PCR
products were subcloned as described above.
Human RNA Dot Blot and Northern Blot Analysis of Human TAP—
Full-length human TAP cDNA was labeled with [32P]dATP using a
random primed DNA labeling kit (Roche Molecular Biochemicals). For
dot blot analysis, the probe was hybridized with a blot containing
poly(A)1 RNA from 50 different human tissues immobilized on a posi-
tively charged nylon membrane (CLONTECH Laboratories, Heidel-
berg, Germany). The hybridization was carried out as described in the
user manual. For Northern blot analysis of human TAP, a multiple
tissue blot (CLONTECH) was probed under high stringency conditions
in accordance with the manufacturer’s instructions.
Cloning of His-hTAP—For protein expression of human TAP, a con-
struct containing a 6-histidine-tag (His) on the carboxyl-terminal site
was designed. The antisense oligonucleotide primer for the PCR en-
coded the hexahistidine residue, the stop codon, and an EcoRI restric-
tion site (59-CCGGAATTCTCAGTGGTGGTGGTGGTGGTGTTTCGG-
GGTGCCTGCCCCCA-39). The sense oligonucleotide primer contained
an NdeI restriction site and the start codon (59-ACAGGGAATTC-
CATATGAGCGGCAGAGTCGGCGA-39). Cloned hTAP was used as
template. The resulting PCR product was subcloned into the pGEM-T
easy vector (Promega) and analyzed as described above. To be able to
induce protein expression, the His-hTAP cDNA was subcloned into the
expression vector pET 29b using the restriction sites for NdeI and
EcoRI and then transformed into Escherichia coli BL21.
In Vitro Expression and Purification of Human His-hTAP—For pro-
tein overexpression the His-hTAP/pET 29b construct was transformed
into E. coli BL21-CodonPlus(DE3)-RIL (Stratagene, La Jolla, CA). Cells
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were grown in a liquid culture to an A600 of 0.6–1.0, and the expression
of His-hTAP was induced with 1 mM isopropylthiogalactopyranoside for
3 h. Cells were harvested by centrifugation at 5000 3 g for 5 min and
resuspended in 32 ml of ice-cold binding buffer (5 mM imidazole, 500 mM
NaCl, 20 mM Tris-HCl, pH 7.9). For disruption of the cells, a French
press with a pressure of 1000 p.s.i. was used. The lysate was centrifuged
at 39,000 3 g for 20 min to remove debris. The supernatant fraction
containing solubilized His-hTAP was used in affinity chromatography
with HiszBind resin (Novagen). A 2.5-ml column was run with 0.5
ml/min, and fractions of 1 ml were collected. Purification of His-hTAP
was achieved in general as described in the user manual using imidaz-
ole for protein elution. His-hTAP was eluted using 200 mM imidazole in
elution buffer (200 mM imidazole, 500 mM NaCl, 20 mM Tris-HCl, pH
7.9), and the collected fractions were neutralized using 1 ml of 80 mM
Tris-HCl, pH 7.0, 20% glycerol. For the detection of His-hTAP protein,
an anti-His6 mouse monoclonal antibody (Roche Molecular Biochemi-
cals) was used together with the enhanced chemiluminescence system
(Amersham Pharmacia Biotech) in accordance to the manufacturers.
Determination of Binding Constants Using the IASys Biosensor—An
IASys single channel resonant mirror biosensor (Fisons Applied Sensor
Technology, Cambridge, UK) (27, 28) was used to measure the kinetic
constants and affinity of His-hTAP to a biotinylated a-tocopherol deriv-
ative. The biotinylated a-tocopherol derivative was obtained by total
synthesis, and its identity as 3,4-dihydro-2,5,7,8-tetramethyl-2-(tride-
cylamidopentyl)-199-(biotinamid)-2H-1-benzopyran-6-ol was deter-
mined by 1H NMR and mass spectrometry.2
Avidin (200-mg excess) was coupled to a sensing cuvette manufac-
tured with a biotin layer, and biotinylated tocopherol (3-mg excess) was
then coupled to the immobilized avidin. Binding of tocopherol was
performed in phosphate-buffered saline containing 10% dimethyl sulf-
oxide. Phosphate-buffered saline buffer, pH 7.2, was used for all other
binding reactions. The reaction vessel was stirred continuously with the
aid of a propeller. Binding was measured at 2-s intervals, and the data
readout from the biosensor was measured in units of arc-seconds. The
reactions were routinely followed for at least 5 min. The kon value for
each binding experiment, as well as the kinetic constants, were calcu-
lated using the “Fast Fit” program (Fisons Applied Sensor Technology)
(29).
Replacement of His-hTAP Bound [3H]-a-Tocopherol with Aternate
Ligands—Radioactive a-[3H]tocopherol (7.9 mg) was dissolved in 100 ml
of water by addition of 2-hydroxypropyl-b-cyclodextrin (144 mg). The
unlabeled ligands were solubilized in water by 2-hydroxypropyl-b-cy-
clodextrin (144 mg in 100 ml) and adjusted to a final concentration of 2.5
mM. The concentrations of the dissolved unlabeled ligands were deter-
mined in water by UV spectrophotometry. The dissolved radioactive
tocopherol (135 ml) was added to 100 ml of purified His-hTAP (10 mg/ml)
in 10 mM Tris, pH 7.4, and incubated overnight at 4 °C. From this
mixture, aliquots of 10 ml were added to 20 ml of the corresponding
nonlabeled ligand and incubated overnight at 4 °C. To this mixture, 600
ml of binding buffer (5 mM imidazole, 500 mM NaCl, 20 mM Tris-HCl, pH
7.9) containing 30 ml of HiszBind resin was added, and after shortly
shaking the mixture the resin was centrifuged at 14,000 3 g for 1 min.
The supernatant was carefully removed, and the resin was washed
sequentially in 1 ml of binding buffer and then in 1 ml of binding buffer
containing 2% BSA. The bound protein was eluted from the resin by
adding 1 ml of elution buffer (1 M imidazole, 500 mM NaCl, 20 mM
Tris-HCl, pH 7.9) containing 2% BSA. After centrifugation, the amount
of a-[3H]tocopherol bound to His-hTAP was determined in the super-
natant by scintillation counting.
RESULTS
Purification of Bovine Tocopherol-associated Protein, TAP—
The identification of the novel cytosolic tocopherol-binding pro-
tein was obtained by a modification of a previously shortly
published protocol (25). The preparation of hepatic cytosol and
the first purification step were performed in accordance to
Kuhlenkamp et al. (30). Hepatic cytosol was incubated with
a-[3H]tocopherol and fractionated by size-exclusion chromatog-
raphy on a Sephacryl S-200 column. A radioactive protein peak
corresponding to a molecular mass range from 30 to 70 kDa
was obtained (Fig. 1A). Further purification by Affi-Gel Blue
affinity chromatography revealed two radioactive protein
peaks (Fig. 1B). To prove that the radioactivity in both peaks
was associated with distinct proteins, native isoelectric focus-
ing was performed. Fractions from peak 1 showed a major
radioactive spot that corresponded to a protein with a pI of 8.1.
The fractions of peak 2 revealed a double signal focusing
around a pI of 6.5 (Fig. 2A). Fractions of both peaks were
irradiated to covalently link the bound a-[3H]tocopherol to the
corresponding proteins. Subsequent fluorography revealed sig-
nals at 46 and at 31 kDa in fractions from peaks 1 and 2,
respectively (Fig. 2B).
The a-tocopherol-transfer protein (a-TTP) from rat liver was
shown to have a molecular mass of 31 kDa with reported
isoforms having pIs of 5.3 and 5.4 (31). This led to the conclu-
sion that the 31-kDa protein peak producing a double band at
pI 6.5 represented the two isoforms of the corresponding bovine
subtype of a-TTP. Thus, the additional protein contained in
peak 1 had to be considered as a novel a-tocopherol-binding
protein. Being the only function known of this novel protein, i.e.2 A. Stocker and S. Zimmer, unpublished results.
FIG. 1. Elution of a-[3H]tocopherol on Sephacryl S-200 gel fil-
tration (A), Affi-Gel Blue affinity chromatography (B), and ion
exchange chromatography (C). The horizontal bars indicate pooled
fractions used for further purification. Broken lines show salt gradients.
See “Experimental Procedures” for details.
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that of associating a-tocopherol (used as a purification criteri-
on), it was named tocopherol-associated protein (TAP). Further
purification of bovine TAP was achieved by cation exchange
chromatography on a Mono S column (Fig. 1C). SDS-PAGE
analysis of the fraction with the highest radioactivity showed
one predominant band at 46 kDa with minor contaminating
proteins (Fig. 3B). A final purification step was performed by
reversed-phase chromatography on a wide pore C4 column
(Fig. 3A). SDS-PAGE analysis revealed one single protein band
with an apparent molecular mass of 46 kDa (Fig. 3B). The
estimation of the molecular mass of the purified native protein
by gel filtration (data not shown) confirmed that bovine TAP
was a monomeric protein with an apparent molecular mass of
46 kDa.
Cyanogen Bromide Cleavage and Peptide Identification—Be-
cause direct sequencing of the amino-terminal end by auto-
mated Edman degradation failed, a cyanogen bromide cleavage
of bovine TAP was performed. This was followed by reversed-
phase HPLC using a C4 column to separate the obtained pep-
tide fragments. From the elution profile two major peaks at 23
and 26 min were fractionated and sequenced. Their Edman
degradation analysis showed two sequences: EV-
LPSQRYNAHLVPEDGSL and FEENYPETLKXLFIVGAP,
representing two peptides of 19 and 18 amino acids,
respectively.
Identification of the Human TAP Gene and Sequence Homol-
ogies—The obtained peptide sequences of bovine TAP were
used to search for known proteins in data banks using the
BLAST sequence alignment program. Both bovine sequences
matched with 84% and 83% identity with a hypothetical pro-
tein of 403 amino acids having a calculated molecular weight of
46,145. This hypothetical protein is coded by a human gene
that is deposited at the EMBL/GenBankTM with accession
number AL096881. Both methionine residues responsible for
cyanogen bromide cleavage of the bovine protein were found to
be conserved in the human sequence, indicating that this pro-
tein represents the human subtype of bovine TAP. The nucle-
otide sequence of human TAP derives from the Homo sapiens
PAC clone DJ130H16, which has been sequenced and mapped
by the Sanger Center chromosome 22 mapping group. The gene
maps within chromosome 22 in region 22q12.1-ter and consists
of 12 exons. A computational analysis indicated that human
TAP is a homologue to a variety of functionally unrelated
proteins (Fig. 4). It was recognized that these proteins share
structurally conserved elements constituting a hydrophobic
lipid binding pocket called CRAL TRIO, the profile of which is
deposited at the PFAM protein family data base (32).
Cloning of Bovine TAP—To confirm that the gene, identified
through the data base analysis, represented the human homo-
logue of TAP, bovine TAP was cloned using the primers coding
for the human sequence. Using total RNA from bovine liver as
template for RT-PCR, a 1.1-kb fragment was obtained showing
the expected size according to the chosen primers. By cloning
the 1.1-kb fragment into the pGEM-T vector and subsequently
sequencing, the identity of the peptides obtained from cyano-
gen bromide cleavage of bovine TAP was confirmed. A compar-
ison of the protein sequences of the bovine fragment of TAP
with human TAP revealed a 95% homology (alignment not
shown).
Cloning of Human TAP—To further study its body distribu-
tion, hTAP was cloned and its cDNA was used for in vitro
expression and Northern analysis studies. RT-PCR was carried
out using total RNA from human intestine and primers con-
taining the 39- or 59-end sequence of human TAP. After ream-
plification the 1.2-kb cDNA fragment was cloned into the
pGEM-T vector. Sequence analysis of the subcloned cDNA con-
firmed that the clone contained the entire open reading frame
of human TAP with a 100% identity on the nucleotide
sequence.
Tissue Distribution of Human TAP—To assess the presence
and relative abundance of hTAP gene transcripts in human
tissues, a commercially available Multiple Tissue Expression
Array (CLONTECH) was used containing poly(A)1 mRNAs
from 50 different human tissues. Hybridization was carried out
with a-[32P]dATP-labeled cDNA of the human TAP clone. Ex-
pression levels of target mRNA were determined by analyzing
the washed blot with a phosphor imager. The results show a
broad tissue distribution of mRNA for hTAP with strong sig-
nals in liver, prostate, and brain tissues (Fig. 5A). To assess the
relative expression levels of mRNA the strongest signal on the
master blot was set to 100%, and all other signals were calcu-
lated as a percentage of it (Fig. 5B). Signals showing an ex-
pression level lower then 5% were neglected because of back-
ground variations. In contrast to the broad tissue distribution
of hTAP in adult tissues, fetal tissues were found to have low
expression levels in the range of the background. Northern
analysis using a multiple tissue blot (CLONTECH) revealed
one major mRNA transcript of approximately 2.8 kb and two
minor transcripts of approximately 4.2 and 1.5 kb. The 2.8-kb
transcript was found to be strongly expressed in liver and brain
FIG. 2. Fluorography of isoelectric
focusing (A) and photographic cross-
linking (B). Radioactive signals in lane 1
at pI of 8.1 and 46 kDa show bTAP. The
signals in lane 2 at pI 6.5 and 31 kDa
show the hypothetical bovine tocopherol
transfer protein.
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and weakly expressed in kidney (Fig. 6). The existence of a
human 2.8-kb mRNA transcript (AL096881) encoding for a
hypothetical protein with homology to Rattus norvegicus 45-
kDa secretory protein (AJ132352) has been proposed recently.
Based on these results and the dot blot analysis described
above, we conclude that the major mRNA transcript of hTAP
has 2818 base pairs and is widely expressed in human tissues,
with the highest levels being found in liver, brain, and prostate.
Cloning of His-hTAP, in Vitro Expression and Purifica-
tion—To permit a convenient protein isolation of hTAP, we
designed a construct containing a His-tag with six carboxyl-
terminal histidine residues. PCR was carried out using an
antisense oligonucleotide primer containing the sequence of the
His-tag, a stop codon, and an EcoRI restriction site for ligation
into the expression vector pET 29b. The sense oligonucleotide
primer contained an NdeI restriction site next to the start
codon. The probe was subcloned into the expression vector pET
29b under the control of the T7lac promoter, and the sequence
of the construct was confirmed through sequence analysis. The
plasmid was transformed into the BL21-CodonPlus(DE3)-RIL
cell line, which contains an additional plasmid coding for argU,
ileY, and leuW tRNA genes to avoid limitation of certain tRNA
species (33). Overexpression of the recombinant His-hTAP pro-
tein was induced with 1 mM isopropylthiogalactopyranoside for
3 h, and protein expression was confirmed by Western blot
analysis using an anti-His6 antibody (Fig. 7B). After cell dis-
ruption with a French press, the recombinant His-hTAP was
located in the soluble fraction. Purification of His-hTAP was
achieved by affinity chromatography using HiszBind resin
charged with Ni21 ions by stepwise increasing imidazole con-
centrations (Fig. 7A).
His-hTAP Binding to Biotinylated a-Tocopherol Derivative
Using the IASys Biosensor—The interaction of His-hTAP with
the immobilized biotinylated a-tocopherol derivative was stud-
FIG. 3. Reversed-phase HPLC of bTAP containing fractions from ion exchange chromatography. A, protein was eluted on a C4
reversed-phase column with a linear acetonitrile gradient (0–100%, 0.1% trifluoroacetic acid). B, SDS-PAGE of purified bTAP (Coomassie
staining). Lane S indicates the fraction from Mono S purification; lanes 36, 37, 38, and 39 represent fractions from the purification by
reversed-phase chromatography.
FIG. 4. Alignment of the CRAL TRIO-domain from human TAP with homologous proteins. Human TAP (amino acids 63–246;
EMBL/GenBanky accession number AL096881) has been aligned with human cellular retinal-binding protein (J04213), human tyrosine phos-
phatase (M83738), squid retinal-binding protein (S68871), 45-kDa secretory protein from rat olfactory epithelium (AJ132352), yeast phosphati-
dylinositol transfer protein (X15483), and human a-tocopherol transfer protein (D49488). Gaps (.) have been inserted to demonstrate maximum
sequence similarity. Residues identical or showing conserved substitution with those of human TAP are indicated with shaded letters. Conserved
amino acid substitutions are defined as pairs of residues belonging to one of the following groups: S/T/P/A/G; N/D/E/Q; H/R/K; M/I/L/V; and F/Y/W.
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ied with the IASys resonant mirror biosensor. In these exper-
iments the biotin label of the derivative was immobilized by
binding to avidin coupled to the biotin surface of a cuvette, and
the binding at different His-hTAP concentrations was moni-
tored over a minimum 5-min period. As shown in Fig. 8 the
derivative consists of a biotin label being attached by an amide
bond to the tail of the synthetic straight-chain R-a-tocopherol
derivative. The plots of the response observed following the
addition of the indicated concentrations of His-hTAP and BSA
show that His-hTAP binds significantly to the tocopherol de-
rivative, whereas no significant binding was observed with
BSA (Fig. 9A). Comparing the plots at different concentrations
the binding of His-hTAP was found to be concentration-depend-
ent in the range of 100 nM to 5 mM. When the binding data for
the interaction of His-hTAP with immobilized tocopherol were
fitted to the double exponential curve, a linear relationship was
observed between kon and ligand concentration according to the
equation kon 5 kdiss 1 kass [ligand] (Fig. 9B). Using this
method, the kass (1.759 6 0.113 3 10
3 M21 s21) and kdiss (8.08 6
2.46 3 1024 s21) values for the interaction are given by the
slope and y intercept of the plot, respectively. Values of disso-
ciation constants (KD) were calculated from the relationship KD
5 kdiss/kass. For the binding of TAP to the tocopherol derivative,
the KD value was calculated to be 4.6 3 10
27 M.
Replacement by Various Ligands for His-hTAP-bound
a-[3H]Tocopherol—To assess the binding specificity of His-
hTAP for various forms of tocopherol and hydrophobic ligands,
FIG. 5. Multiple tissue expression analysis of hTAP. A, autora-
diogram of human RNA master blot (CLONTECH) hybridized with a
32P-labeled cDNA of hTAP. B, dot-to-dot variations are expressed as
percentage of maximal intensity relative to the liver tissue.
FIG. 6. Northern analysis of hTAP. The size distribution of the
hTAP transcript was analyzed using a human multiple tissue Northern
blot (CLONTECH) hybridized with a 32P-labeled cDNA of hTAP.
FIG. 7. Analysis of purification of His-hTAP. The purification of
recombinant His-hTAP was followed by SDS-PAGE (A) and Western
blotting (B). Lane 1 shows the molecular weight standard, lanes 2 and
3 show the E. coli supernatants uninduced and after induction. In the
residual lanes the elution of pure His-hTAP on Ni-NTA-Sepharose
using 200 mM imidazole is depicted.
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replacement of a-[3H]tocopherol by a 64-fold excess of each
alternative ligand was determined. The results of Table I rep-
resent the average of duplicate experiments 6 S.E. Tocopherols
were the most efficient species in replacing His-hTAP-bound
a-[3H]tocopherol followed by biotinylated a-tocopherol deriva-
tive. 3-sn-Phosphatidylcholine appeared to be without effect.
DISCUSSION
Strategy to Reveal the Existence of a New a-Tocopherol-Bind-
ing Protein—The present study describes the finding, cloning,
and in vitro expression of the human gene encoding the toco-
pherol-associated protein (hTAP). Initial investigations on the
cellular distribution of vitamin E have led to the identification
of a novel cytosolic protein (bTAP) from bovine liver that binds
radioactively labeled a-tocopherol. Peptide mapping of bTAP
revealed two peptide sequences matching with high homology
to a human gene encoding for a 403-amino acid protein of
unknown function. To obtain conclusive evidence for the hy-
pothesis that this protein was identical with the human sub-
type of bTAP a 1.1-kb fragment of the bovine gene was ampli-
fied by RT-PCR using primers deriving from the human gene
and bovine RNA as template. The high degree (95%) of se-
quence homology of the amplicon gave unequivocal evidence
that this gene represents the human subtype of bTAP.
Tocopherol Binding by His-hTAP—a-Tocopherol appears to
be specifically selected in the human body and exerts specific
functions uniquely related to its structure. The former event is
performed by the liver a-TTP; the latter are a-tocopherol ex-
clusive actions at the level of cell signal transduction that
result in a-tocopherol-dependent gene expression. How does
the regulation of signal transduction and gene expression by
a-tocopherol take place? Is there a need for a cellular protein
recognizing a-tocopherol? To establish if hTAP may play such a
role, the interaction between the protein and tocopherol was
investigated. The technique employed simulates the in vivo
situation where a cytosolic protein (hTAP) accesses a hydro-
phobic surface (the membrane) that contains a-tocopherol. A
biotinylated a-tocopherol derivative was immobilized and used
as a ligand for the binding measurements performed using an
IASys-resonant mirror system and recombinant His-hTAP.
The biotinylated a-tocopherol has been shown (cf. Table I) to
bind with hTAP, as indicated by the competition experiments
with hTAP-bound radioactive a-tocopherol, although with a
lower affinity. The obtained data show a dose-dependent satu-
rable binding of His-hTAP to the biotinylated tocopherol, and
at the same time they have excluded the possibility of nonspe-
cific interactions as shown by the absence of binding of BSA.
The data show a dissociation constant of 4.6 3 1027 M. This
suggests that the recombinant His-hTAP is expressed with a
functional lipid-binding domain and that it binds to biotiny-
lated tocopherol well within physiological concentrations. How-
ever, the efficiency of cold a-tocopherol in competing with the
FIG. 8. Biotinylated a-tocopherol derivative. The structure of
total synthetic biotinylated a-tocopherol, as confirmed by 1H NMR and
mass spectrometry; the proposed systematic name is given underneath.
FIG. 9. Interaction analysis of soluble His-hTAP with the im-
mobilized biotinylated a-tocopherol derivative. A, comparison of
the interaction of 100 mg of His-hTAP and 100 mg of BSA with immo-
bilized, biotinylated a-tocopherol derivative via avidin, coupled to the
biotin surface of a cuvette. The measurements were made by an IASys
resonant mirror biosensor. A saturating response of 800 arc-seconds
was observed for His-hTAP, equivalent to 1.5 ng/mm2, according to the
information supplied by the manufacturer for planar cuvette surfaces.
B, determination of binding constants for the interaction of His-hTAP
with immobilized biotinylated a-tocopherol from three separate exper-
iments, using the IASys resonant mirror biosensor. For each concen-
tration of His-hTAP, the rate constants (kon) were determined by the
linearization procedure using the Fast Fit program. The plot of kon
versus His-hTAP concentrations gave a straight line with a slope rep-
resenting kass and the intercept with the y axis equivalent to kdiss. The
calculated correlation coefficient for this data is 0.982.
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hot hTAP-bound one is higher than that of the biotinylated
form. This indicates that the dissociation constant obtained
with this method is underestimated.
These findings are also compatible with an in vivo role of
hTAP in tocopherol-mediated intracellular functions. The spec-
ificity of a-tocopherol binding to hTAP has been studied by
competition experiments between radioactive a-tocopherol
bound to hTAP and a number of hydrophobic molecules dis-
solved in the aqueous medium by b-cyclodextrin. The use of a
radioactive assay, the only one available at the present mo-
ment, has limited the analysis to the question of tocopherol
specificity in comparison with other ligands. Further studies on
the relative affinity of the different tocopherols require the
development of a more sensitive assay. However, it was already
possible to show that more a-tocopherol remains bound to the
His-hTAP when biotinylated tocopherol is used as a competitor.
All other tocopherols were equally effective at the concentra-
tions used (1.7 mM). A titration of the release of bound a-to-
copherol at lower concentrations of other tocopherols would be
needed to establish their relative affinities, but the assay pre-
cision does not permit this information to be obtained.
Analogy with CRAL Proteins—The structural analysis of
hTAP indicates that it is a member of the widespread SEC14-
like protein family. All members of this family have a common
conserved lipid-binding domain called CRAL TRIO. The struc-
tural determinants of the CRAL TRIO domain have been iden-
tified by Sha et al. (34) by resolving the crystal structure of the
phosphatidylinositol transfer protein from yeast (SEC14). The
SEC14 gene product has been shown to play an essential role in
yeast Golgi function. The presence of an SEC14-like lipid-
binding domain in hTAP indicates that this region may be
involved in hTAP membrane localization. In contrast to SEC14
and a-TTP, the hTAP gene product contains a unique 157-
amino acid carboxyl-terminal extension. The strong overall
sequence homology of hTAP with the 45-kDa secretory protein
from rat (AJ132352), which also contains this extension, indi-
cates that both proteins are closely related. The 45-kDa rat
secretory protein is present in cells of the olfactory epithelium,
the apical region of the trachea, the surface layer of the ciliated
bronchial epithelium, and the epidermis (35). Opposite to this,
hTAP mRNA is ubiquitous and strongly expressed exclusively
in adult tissues.
The possibility that hTAP represents an additional a-tocoph-
erol transfer protein cannot be excluded. However, in contrast
to a-TTP, which is present essentially only in the liver (36),
hTAP mRNA is ubiquitous and present in liver, in the prostate,
and in brain in larger amounts. a-TTP lacks the carboxyl
terminus domain, which suggests there is a different functional
role for hTAP. Affinity data of a-TTP that suggest a recognition
of the different tocopherols and tocotrienols cannot yet be ob-
tained for TAP, although the latter can distinguish between
tocopherols and other hydrophobic ligands as well as biotiny-
lated tocopherol.
Possible Function of hTAP—The presence of hTAP expres-
sion in almost all tissues, although in different amounts, is
indicative of an important general cellular function of this
protein. Its lack in fetus liver may suggest also an embryoge-
netic role.
The search for an hTAP function may be guided by results
obtained with analogous proteins. SEC14 has been suggested
to play a role in phospholipid exchange (37, 38). The GTP
binding motive, found to be present together with GTP binding
in TAP,3 is similar to what has been described for the rat
secretory protein (39). A GTP binding/GTPase activity may be
important to confer to hTAP regulation properties in its a-to-
copherol redistribution function. Proteins having SEC14-like
domains can interact with ras21 and through this binding be
able to suppress ras21 activity (40).
Conclusions—In conclusion, intracellular proteins with the
ability to bind and redistribute a-tocopherol as well as a-to-
copherol receptor molecules appear to be needed to fully un-
derstand the mechanism of action of this molecule. It is still too
early to state if hTAP is one or the other, but in either case
hTAP may be an important molecule (or a member of a family
of molecules) capable of binding a-tocopherol and responsible
for important intracellular events.
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